Open company graph database — free web & API
Login

AskAt Inc.

株式会社AskAt
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
0
§01

Basic information

BASIC
Head office
4th Floor, STATION Ai, 1-2-32 Tsuruma, Showa-ku, Nagoya-shi, Aichi Prefecture, 466-0064
Chief executive
Nobuyuki Koizumi
Capital
91,144,500
Employees (non-consolidated)
Employees (consolidated)
Start date
2013-01-07
End date
§02

Websites

1 DOMAINS
§03

Business

5
Pharmaceutical research and developmentPharmaceutical licensing agreementsPharmaceutical salesPharmaceutical clinical trialsAdvisory services
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

22 EVENTS

The journey of AskAt starting from January 2013Sources

Established as a 100% subsidiary of Rakuoira Pharmaceutical Co., Ltd. : President Nobuyuki Koizumi : Acquired intellectual property related to the following compounds from Rakuoira Pharmaceutical: • EP4 antagonist / AAT-007, AAT-008 • 5-HT4 partial agonist / AAT-009 • COX-2 inhibitor / AAT-076Sources

Acquired management rights from Rakuoira Pharmaceutical Co., Ltd.Sources

Relocated headquarters to Showa-ku, Nagoya CitySources

Akihiro Furuta appointed president : Dissolved consolidation with Rakuoira Pharmaceutical Co., Ltd. and became fully independentSources

Acquired intellectual property of CB2 agonist from Rakuoira Pharmaceutical Co., Ltd.Sources

Signed a licensing agreement in China for AAT-076 and AAT-007 with RMX Co. (now Haihe Co.)Sources

Signed a licensing agreement in China for AAT-007 with Ningbo Tai Kang Medical Technology Co.Sources

EP4 antagonist Galliprant® began sales in the United States by Aratana Therapeutics Co. (now a subsidiary of Elanco Animal Health Co.)Sources

Signed a worldwide (excluding China and Taiwan) licensing agreement for AAT-007 and AAT-008 with Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology Co.)Sources

Signed a worldwide licensing agreement for AAT-008 in the veterinary drug field with Aratana Therapeutics Co. (now a subsidiary of Elanco Animal Health Co.)Sources

Relocated headquarters to Nakamura-ku, Nagoya CitySources

RMX Co. (now Haihe Co.) began clinical trials of EP4 antagonist AAT-007 in the People's Republic of ChinaSources

Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology Co.) began a colorectal cancer clinical trial in the United States using AAT-007 in combination with PembrolizumabSources

Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology Co.) began a Phase 1b/2 trial of AAT-007 for non‑small cell lung cancer in collaboration with Merck in the United StatesSources

Elanco Animal Health and Aratana Therapeutics Inc. launch EP4 antagonist Galliprant® in EuropeSources

Ningbo NewBay Medical Technology Co., Ltd. begins clinical trials of EP4 antagonist AAT-007 in the oncology field in ChinaSources

Oxford Cannabinoid Technologies Co. signs a worldwide licensing agreement for CB2 receptor agonist AAT-730, excluding JapanSources

RMX Co. (now Haihe Co.) begins clinical trials of COX-2 inhibitor AAT-076 in the pain field in ChinaSources

Velo-1 Co. signs an animal drug licensing agreement for AAT-076Sources

Aratana Therapeutics Co. (now a subsidiary of Elanco Animal Health) terminates the worldwide licensing agreement for AAT-008 in the animal drug fieldSources

Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology) terminates the worldwide licensing agreement for AAT-007 and AAT-008, excluding China and TaiwanSources

§07

News

3 ARTICLES

AAT-730 Patent Registered in the United StatesSources

AskAt Inc. announced that the U.S. Patent and Trademark Office issued a continuation patent covering salts and crystal forms of AAT-730, a CB2 agonist, for which the company filed an application in 2021. This further strengthens the company's U.S. intellectual property rights related to AAT-730.

13th Fiscal Year Financial Results Notice PublishedSources

AskAt Inc. published its financial results notice for its 13th fiscal year on the electronic public notices page on March 23, 2026. See the page for details.

AskAt Terminates AAT-730 License AgreementSources

AskAt Inc. terminated its license agreement with Oxford Cannabinoid Technologies Ltd. for AAT-730, a CB2 agonist, due to a breach of contract. The company is seeking a new partner to continue development of the drug.

§08

Public records

GOV
National Tax Agency basic information6180001108273
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社AskAt
Trade name (kana)
アスカット
Name in English
Corporation type
301
Address
〒466-0064 愛知県名古屋市昭和区鶴舞1丁目2番32号
Postal code
4660064
Prefecture code
23
City code
107
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-06-13
Change date
2025-06-04
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
3650722
METI gBizINFO6180001108273
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6180001108273
Trade name
株式会社AskAt
Trade name (kana)
アスカット
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
愛知県名古屋市昭和区鶴舞1丁目2番32号
Postal code
4660064
Prefecture
愛知県
Prefecture code
23
City or district
名古屋市昭和区
City code
107
Street address
鶴舞1丁目2番32号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2025-06-13
Key information
6180001108273
§09

Sources & updates

SOURCES
↑